about
The Warburg effect and drug resistancePresent and future pharmacotherapeutic agents in heart failure: an evolving paradigmExercise effects on perivascular adipose tissue: endocrine and paracrine determinants of vascular function.Pharmacogenomics of off-target adverse drug reactions.An S-warfarin and AZD1981 interaction: in vitro and clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator.Identification of novel inhibitors of the amino acid transporter B0 AT1 (SLC6A19), a potential target to induce protein restriction and to treat type 2 diabetes.Redox-based therapeutics in neurodegenerative disease.Neurosteroid biosynthesis downregulation and changes in GABAA receptor subunit composition: A biomarker axis in stress-induced cognitive and emotional impairment.Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.Treatment and management of chronic fatigue syndrome/myalgic encephalomyelitis: all roads lead to Rome.NVP-TAE684 reverses multidrug resistance (MDR) in human osteosarcoma by inhibiting P-glycoprotein (PGP1) function.Mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone induces vasorelaxation without involving KATP channel activation in smooth muscle cells of arteriesInvestigation of the predictive validity of laser-EPs in normal, UVB-inflamed and capsaicin-irritated skin with four analgesic compounds in healthy volunteers.Comparing intravenous and oral proton pump inhibitor therapy for bleeding peptic ulcers following endoscopic management: a systematic review and meta-analysis.Interruption to antiplatelet therapy early after acute ischaemic stroke: a nested case-control study.Presynaptic, release-regulating mGlu2 -preferring and mGlu3 -preferring autoreceptors in CNS: pharmacological profiles and functional roles in demyelinating diseaseTrimetazidine does not alter metabolic substrate oxidation in cardiac mitochondria of target patient population.Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjectsThe pregnane X receptor down-regulates organic cation transporter 1 (SLC22A1) in human hepatocytes by competing for ("squelching") SRC-1 coactivatorEffects of glucagon-like peptide-1 on the differentiation and metabolism of human adipocytes.Inhibition of fatty acid synthase is protective in pulmonary hypertension.Genetic fusion of human FGF21 to a synthetic polypeptide improves pharmacokinetics and pharmacodynamics in a mouse model of obesity.Preclinical studies of VS-505: a non-absorbable highly effective phosphate binder.Functional modulation of glycine receptors by the alkaloid gelsemine.Obestatin as a key regulator of metabolism and cardiovascular function with emerging therapeutic potential for diabetes.Identification of A3 adenosine receptor agonists as novel non-narcotic analgesics.Phase I metabolites of mephedrone display biological activity as substrates at monoamine transporters.Mutation in SLC6A9 encoding a glycine transporter causes a novel form of non-ketotic hyperglycinemia in humans.Edoxaban drug-drug interactions with ketoconazole, erythromycin, and cyclosporine.Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.Endothelin-1 suppresses insulin-stimulated Akt phosphorylation and glucose uptake via GPCR kinase 2 in skeletal muscle cells.Fenofibrate inhibits atrial metabolic remodelling in atrial fibrillation through PPAR-α/sirtuin 1/PGC-1α pathway.Blockade of the 5-HT transporter contributes to the behavioural, neuronal and molecular effects of cocaine.Structure-activity relationship studies of citalopram derivatives: examining substituents conferring selectivity for the allosteric site in the 5-HT transporterChanges in the plasma membrane in metabolic disease: impact of the membrane environment on G protein-coupled receptor structure and function.Tenapanor administration and the activity of the H+ -coupled transporter PepT1 in healthy volunteers.Microglia antioxidant systems and redox signalling.D-512, a novel dopamine D2/3 receptor agonist, demonstrates greater anti-Parkinsonian efficacy than ropinirole in Parkinsonian rats.Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies.Inhibition of JNK signalling mediates PPARα-dependent protection against intrahepatic cholestasis by fenofibrate.
P2860
Q26770007-33BFF916-A16D-4AC3-AC74-FE4574E6EAD7Q28077186-DBD1237F-03BF-42E0-8DD0-CA041A635DA3Q30238666-A6743D6E-05AD-44BC-91B4-42BA775B512CQ30400366-E26902F3-A11A-48AA-9639-8ABF0A184349Q31123470-A2C1E507-A445-4643-98B9-17AA3EF07FAFQ32182366-7DF983E9-FF80-465B-9DF4-8C28C23038CFQ34535918-123C20F5-1B66-4281-B22B-B393A3A36748Q34556039-A4D7D14E-6D14-45C2-AC4D-8018A10F3D2EQ34556733-6C2D69E4-30E4-4657-B2E4-518C17A0B832Q34680436-3555A1A3-44FC-4086-97EB-0867E95BD4D0Q35851832-71744768-8638-4EE8-94A8-7A97E76AD86AQ36106217-24A88359-6C39-436A-9501-55BE61523C52Q36264439-1FBF397A-AF61-4FF7-8E26-83E9E39EC2BCQ36274916-20ECE74C-9B39-4BE5-8728-1BEC798853B9Q36310002-44F3EA22-F320-4C3D-AB04-7C0C2595DD74Q36797353-26363015-5308-4B28-BBD1-2A8B7392BD98Q36797382-741E32B3-E8F6-477F-A0C5-4317A059E230Q36830103-4982040A-B146-4C92-B0BB-8F16F8C04B56Q36830111-A7FA4435-B45D-4E43-8CBA-70AAE9EB7065Q36903400-3F5C0E77-EF1C-45F1-91D7-CD631400D38BQ36941262-97A37800-7B14-4CEE-A5E7-EE6CE6E1D07FQ37034745-7E2FC86C-F1A2-49AD-B9C5-D7550977C1C2Q37034750-FE12970C-98F0-4617-92B2-682814FA3158Q37034758-F934217B-DAEB-4DB3-9F72-613083544E70Q37034764-D15CFF75-D123-4906-989A-74D196B67636Q37084901-6D3A6A16-5E9C-4FF2-A7CC-4B0E802D048DQ37161370-ED68B940-952E-400C-8C54-88545118E70AQ37314174-3F9907EF-2ED8-4484-B334-E8855F89B995Q37399582-9D4552B4-5575-4A5F-8BE8-CE58C155C434Q37399585-820772DD-B957-4AE8-9E39-115852A2CF2AQ37686147-06A71099-B1A6-49BB-8739-15700DD3499CQ37686153-142B831B-AECB-48C7-99C9-A0B6DAD269E0Q38430705-29BDF653-2E72-4A05-A95E-BD0CAA397D2AQ38572969-423898EF-F22A-4F11-9CD4-D268A5776B9FQ38687050-32439649-1C31-4DED-A5FD-55B5E4FFB921Q38692100-2F386BE6-4DD7-4B1F-B51D-9F1D7406DE52Q38692790-828E224A-3AA8-40CE-B199-DFF39DAB7DA8Q38699002-0113F608-89FD-438B-9191-09EB31E97D95Q38699013-4873A170-EA04-44AE-93D6-F01830290E67Q38711012-8481D6AC-149B-4C83-9EDB-61A5C4FCB55E
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The Concise Guide to PHARMACOLOGY 2015/16: Transporters
@ast
The Concise Guide to PHARMACOLOGY 2015/16: Transporters
@en
The Concise Guide to PHARMACOLOGY 2015/16: Transporters
@nl
type
label
The Concise Guide to PHARMACOLOGY 2015/16: Transporters
@ast
The Concise Guide to PHARMACOLOGY 2015/16: Transporters
@en
The Concise Guide to PHARMACOLOGY 2015/16: Transporters
@nl
prefLabel
The Concise Guide to PHARMACOLOGY 2015/16: Transporters
@ast
The Concise Guide to PHARMACOLOGY 2015/16: Transporters
@en
The Concise Guide to PHARMACOLOGY 2015/16: Transporters
@nl
P2093
P50
P3181
P356
P1476
The Concise Guide to PHARMACOLOGY 2015/16: Transporters
@en
P2093
CGTP Collaborators
Eamonn Kelly
Helen E Benson
John A Peters
Neil Marrion
P304
P3181
P356
10.1111/BPH.13355
P407
P577
2015-12-01T00:00:00Z